Literature DB >> 29876481

Data on the epidemiology of heart failure in Sub-Saharan Africa.

Ulrich Flore Nyaga1, Jean Joel Bigna2, Valirie N Agbor3, Mickael Essouma1, Ntobeko A B Ntusi4,5,6, Jean Jacques Noubiap4.   

Abstract

In Sub-Saharan Africa (SSA), chronic non-communicable diseases and cardiovascular diseases in particular, are progressively taking over infectious diseases as the leading cause of morbidity and mortality. Heart failure is a major public health problem in the region. We summarize here available data on the prevalence, aetiologies, treatment, rates and predictors of mortality due to heart failure in SSA.

Entities:  

Keywords:  Aetiologies; Heart failure; Mortality; Prevalence; Sub-Saharan Africa; Treatment

Year:  2018        PMID: 29876481      PMCID: PMC5988512          DOI: 10.1016/j.dib.2018.01.100

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Value of the data This work provides a deeper understanding of the prevalence, etiologies and prognosis of heart failure in SSA. The data allow examination of the different medications used for the treatment of heart failure and therefore could help in changing practices for an optimal management of this pathology. The data could be used as a baseline for comparison in future studies.

Data

In SSA, heart failure is a major public health problem, associated with high morbidity and mortality. Due to the shortage of data to distinctly understand the epidemiology of this pathology in this part of the world, we present here a summary of available data on the prevalence, aetiology, treatment, and prognosis of heart failure in SSA.

Experimental design, materials, and methods

Through a systematic literature search in MEDLINE and EMBASE (search strategies are presented in Table 1, Table 2), we included all published studies from January 1, 1996 to June 23, 2017 with available data on the prevalence, incidence, aetiologies, diagnosis, treatment and outcomes of heart failure in patients aged 12 years and older, living in SSA. We excluded studies conducted exclusively on African populations living outside Africa, commentaries, editorials, letters to the editor, case reports and case-series of less than 30 participants, studies lacking relevant data to compute the prevalence of the different heart failure aetiologies or treatment, and for duplicate studies, the most comprehensive and/or recent study with the largest sample size was considered, studies with inaccessible full-text, even after request from the corresponding author.
Table 1

Main search strategy for PubMed.

SearchSearch termHits
1Heart failure [tiab] OR cardiac failure [tiab] OR cardiac insufficiency [tiab] OR heart disease [tiab]276, 088
2(((Africa* [tiab] OR Benin [tiab] OR Botswana [tiab] OR "Burkina Faso" [tiab] OR Burundi [tiab] OR Cameroon [tiab] OR "Canary Islands" [tiab] OR "Cape Verde" [tiab] OR "Central African Republic" [tiab] OR Chad [tiab] OR Comoros [tiab] OR Congo [tiab] OR "Democratic Republic of Congo" [tiab] OR Djibouti [tiab] OR "Equatorial Guinea" [tiab] OR Eritrea [tiab] OR Ethiopia [tiab] OR Gabon [tiab] OR Gambia [tiab] OR Ghana [tiab] OR Guinea [tiab] OR "Guinea Bissau" [tiab] OR "Ivory Coast" [tiab] OR "Cote d'Ivoire" [tiab] OR Jamahiriya [tiab] OR Kenya [tiab] OR Lesotho [tiab] OR Liberia [tiab] OR Madagascar [tiab] OR Malawi [tiab] OR Mali [tiab] OR Mauritania [tiab] OR Mauritius [tiab] OR Mayotte [tiab] OR Mozambique [tiab] OR Namibia [tiab] OR Niger [tiab] OR Nigeria [tiab] OR Principe [tiab] OR Reunion [tiab] OR Rwanda [tiab] OR "Sao Tome" [tiab] OR Senegal [tiab] OR Seychelles [tiab] OR "Sierra Leone" [tiab] OR Somalia [tiab] OR "South Africa" [tiab OR "St Helena" [tiab] OR Swaziland [tiab] OR Tanzania [tiab] OR Togo [tiab] OR Uganda [tiab] OR Zaire [tiab] OR Zambia [tiab] OR Zimbabwe [tiab] OR "Central Africa" [tiab] OR "Central African" [tiab] OR "West Africa" [tiab] OR "West African" [tiab] OR "Western Africa" [tiab] OR "Western African" [tiab] OR "East Africa" [tiab] OR "East African" [tiab] OR "Eastern Africa" [tiab] OR "Eastern African" [tiab] OR "South African" [tiab] OR "Southern Africa" [tiab] OR "Southern African" [tiab] OR "sub Saharan Africa" [tiab] OR "sub Saharan African" [tiab] OR "subSaharan Africa" [tiab] OR "subSaharan African" [tiab]) NOT ("guinea pig" [tiab] OR "guinea pigs" [tiab] OR "aspergillus niger [tiab]"))) AND (Heart failure [tiab] OR cardiac failure [tiab] OR cardiac insufficiency [tiab] OR heart disease [tiab])
3#1 AND #25012
4#3 AND Search limits: From 1 January 1996 to 10 Oct 20172125
Table 2

Main search strategy for EMBASE.

#1‘Heart failure’ OR ‘cardiac failure’ OR ‘cardiac insufficiency’ OR ‘heart disease’658,990
#2'africa':ab,ti OR 'algeria':ab,ti OR 'angola':ab,ti OR 'benin':ab,ti OR 'botswana':ab,ti OR 'burkina faso':ab,ti OR 'burundi':ab,ti OR 'cameroon':ab,ti OR 'canary islands':ab,ti OR 'cape verde':ab,ti OR 'central african republic':ab,ti OR 'chad':ab,ti OR 'comoros':ab,ti OR 'congo':ab,ti OR 'democratic republic of congo':ab,ti OR 'djibouti':ab,ti OR 'egypt':ab,ti OR 'equatorial guinea':ab,ti OR 'eritrea':ab,ti OR 'ethiopia':ab,ti OR 'gabon':ab,ti OR 'gambia':ab,ti OR 'ghana':ab,ti OR 'guinea':ab,ti OR 'guinea bissau':ab,ti OR 'ivory coast':ab,ti OR 'cote d ivoire':ab,ti OR 'jamahiriya':ab,ti OR 'kenya':ab,ti OR 'lesotho':ab,ti OR 'liberia':ab,ti OR 'libya':ab,ti OR 'madagascar':ab,ti OR 'malawi':ab,ti OR 'mali':ab,ti OR 'mauritania':ab,ti OR 'mauritius':ab,ti OR 'mayotte':ab,ti OR 'morocco':ab,ti OR 'mozambique':ab,ti OR 'namibia':ab,ti OR 'niger':ab,ti OR 'nigeria':ab,ti OR 'principe':ab,ti OR 'reunion':ab,ti OR 'rwanda':ab,ti OR 'sao tome':ab,ti OR 'senegal':ab,ti OR 'seychelles':ab,ti OR 'sierra leone':ab,ti OR 'somalia':ab,ti OR 'south africa':ab,ti OR 'st helena':ab,ti OR 'sudan':ab,ti OR 'swaziland':ab,ti OR 'tanzania':ab,ti OR 'togo':ab,ti OR 'tunisia':ab,ti OR 'uganda':ab,ti OR 'western sahara':ab,ti OR 'zaire':ab,ti OR 'zambia':ab,ti OR 'zimbabwe':ab,ti OR 'central africa':ab,ti OR 'central african':ab,ti OR 'west africa':ab,ti OR 'west african':ab,ti OR 'western africa':ab,ti OR 'western african':ab,ti OR 'east africa':ab,ti OR 'east african':ab,ti OR 'eastern africa':ab,ti OR 'eastern african':ab,ti OR 'north africa':ab,ti OR 'north african':ab,ti OR 'northern africa':ab,ti OR 'northern african':ab,ti OR 'south african':ab,ti OR 'southern africa':ab,ti OR 'southern african':ab,ti OR 'sub saharan africa':ab,ti OR 'sub saharan african':ab,ti OR 'subsaharan africa':ab,ti OR 'subsaharan african':ab,ti408,647
#3#1 AND #24165
#4#3 AND Search limits: From 1 January 1996 to 10 Oct 20171660
Main search strategy for PubMed. Main search strategy for EMBASE. The titles and abstracts of articles retrieved from the bibliographic searches were independently screened by two investigators and full-texts of potentially eligible studies were retrieved and assessed for final inclusion. All discrepancies the selection of studies were resolved through discussion or with the arbitrage of a third investigator. A total of 35 studies were included in this review [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35]. A summary of the selection process is presented in the Fig. 1.
Fig. 1

PRISMA flow chart of study selection.

PRISMA flow chart of study selection. Data were then extracted using a predesigned data extraction form. The extracted data include: the last name of first author and the year of study publication, the country in which the study was conducted, Region (Western, Southern, Central, Eastern), area (urban, semi-urban or rural), study design (cross-sectional, cohort, case control), data collection (prospective versus retrospective), random sampling (yes versus no), study population, male proportion, mean or median age (in years), age range (in years), sample size, criteria used for the diagnosis of heart failure, number of cases of the different aetiologies of heart failure and number of cases of the different medications used for the treatment of heart failure. The quality and risk of bias of all included studies are presented in Table 3, Table 4, Table 5, Table 6, Table 7. It was assessed using the risk of bias assessment tool for developed by Hoy et al. [36]. This tool was adapted for the different topics on heart failure covered in this review (prevalence, aetiology, treatment and prognosis of heart failure).
Table 3

Summary table of included studies reporting on heart failure in sub-Saharan Africa (1996–2017).

First name of author, publication yearCountryRegionAreaStudy designStudy settingData collectionStudy populationRandom samplingMale (%)Mean age (in years)Age range (in years)Sample sizeCriteria for diagnosis of HF
Oyoo, 1999 [1]KenyaEasternUrbanCross-sectionalHospital-basedProspectivePatients ≥13 years admitted for congestive heart failureNo48.4NR≥1391NR
Thiam, 2003 [2]SenegalWesternUrbanCross-sectionalHospital- basedProspectivePatients suffering from heart failureNoNR50.012–91170NR
Kingue, 2005 [3]CameroonCentralUrbanCross-sectionalHospital-basedRetrospective and prospectivePatients presenting with clinical and echocardiographic signs of heart failureNo59.357.3≥16167NR
Familoni, 2007 [4]NigeriaWesternSemi-urbanCross-sectionalHospital-basedProspectivePatients presenting with acute heart failureNo61.757.6NR82NR
Owusu, 2007 [5]GhanaWesternUrbanCross-sectionalHospital-basedProspectivePatients above 12 years admitted with diagnosis of heart failureNo51.551.113–90167Framingham's criteria
Stewart, 2008 [6]South AfricaSouthernUrbanCross-sectionalHospital-basedProspectiveNovo presentations in patients with heart failure and related cardiomyopathiesNo4355.0NR884European Society of Cardiology (ESC) guidelines on HF
Ogah, 2008 [7]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveAll cases of echocardiography done in the department of medicine between September 2005 and February 2007No51.654.015–901441NR
Onwuchekwa, 2009 [8]NigeriaWesternNRCross-sectionalHospital-basedRetrospectiveCongestive cardiac failure cases admitted and/or discharged from the medical wardsNo57.254.418–100423Framingham's criteria
Maro, 2009 [9]TanzaniaEasternUrbanCohortHospital-basedProspectivePatients admitted for congestive heart failureNo55.0NRNR390Framingham's criteria
Damasceno, 2012 [10]The THESUS-HF registrySSACohortHospital-basedProspectivePatients admitted with acute heart failureNo49.252.3˃121006European Society of Cardiology (ESC) guidelines on HF
Chansa, 2012 [11]ZambiaSouthernUrbanCohortHospital-basedProspectiveAdult patients (>18 years) admitted for acute heart failureNo4150>18390European Society of Cardiology guidelines on HF
Kwan, 2013 [12]RwandaEasternRuralCross-sectionalHospital-basedRetrospectiveHeart failure patients treated between November 2006 and march 2011No30.0NRNR138NR
Massouré, 2013 [13]DjiboutiEasternNRCohortHospital-basedProspectiveDjiboutian adults hospitalized for heart failureNo84.055.827–7545Framingham's criteria
Ojji, 2013 [14]NigeriaWesternUrbanCross-sectionalHospital-basedProspectiveSubjects of African descent with novo presentations of heart diseaseNo49.349.0NR1515European Society of Cardiology guidelines on HF
Sliwa, 2013 [15]The THESUS-HF registrySSACohortHospital-basedProspectivePatients presenting with acute heart failureNo49.152.3>121006European Society of Cardiology guidelines on HF
Makubi, 2014 [16]TanzaniaEasternUrbanCohortHospital-basedProspectivePatients ≥ 18 years of age with heart failure defined by the Framingham criteriaNo49.055.0≥18427Framingham's criteria
Ogah, 2014 [17]NigeriaWesternUrbanCross-sectionalHospital-basedProspectivePatients presenting with acute heart failureNo54.956.4NR452Framingham's criteria and ESC
Pio, 2014 [18]TogoWesternUrbanCross-sectionalHospital-basedProspectiveHospitalized patients with heart failureNo48.252.218–106297European Society of Cardiology guidelines on HF
Pio, 2014 [19]TogoWesternUrbanCross-sectionalHospital-basedRetrospectiveFiles of patients hospitalized with heart failureNoNR36.518–45376NR
Osuji, 2014 [20]NigeriaWesternNRCross-sectionalHospital-basedRetrospectiveAll medical admissionNo50.560.718–110537NR
Okello, 2014 [21]UgandaEasternNRCohortHospital-basedRetrospectivePatients admitted for acute heart failureNo30.352NR274NR
Dokainish, 2015 [22]The INTER-CHF registrySSACohortHospital-basedProspective, international, multicenterAmbulatory and hospitalized adult patients with heart failureYes51.853.4≥181294Boston criteria of HF
Adeoti, 2015 [23]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveAll medical admissionsNo55.050.916–1023750NR
Ansa, 2016 [24]NigeriaWesternNRCross-sectionalHospital-basedRetrospective medical record reviewAll cardiovascular admissions to the medical wardsNoNRNR≥18144NR
Abebe 2016 [25]EthiopiaEasternUrbanChart reviewHospital-basedRetrospectiveMedical records of patients admitted for heart failureNR30.253.6NR311NR
Ali, 2016 [26]EthiopiaEasternUrbanCohortHospital-basedProspectiveAdult patients (>18 years) admitted for heart failureNo50.750.9NR152Framingham's criteria
Kingery, 2017 [27]TanzaniaEasternUrbanCohortHospital-basedProspectiveMedical inpatients admitted for heart failureNo44.152.0≥18145Framingham's criteria
Boombhi, 2017 [28]CameroonCentralUrbanCross-sectionalHospital-basedRetrospectivePatients hospitalized for acute heart failure, diagnosed on clinical and/or ultrasound evidenceNo42.761,516–95148NR
Traore, 2017 [29]Ivory CoastWesternUrbanCross-sectionalHospital-basedRetrospectivePatients hospitalized for heart failureNo51.0NRNR257NR
Bonsu, 2017 [30]GhanaWesternUrbanCohortHospital-basedRetrospectiveIndividuals aged ≥ 18 years discharged from first heart failure admissionNo45.660.3≥181488Framingham's criteria
Mwita, 2017 [31]BotswanaSouthernUrbanCohortHospital-basedProspectivePatients admitted with acute heart failureNo53.954.220–89193NR
Pallangyo 2017 [32]TanzaniaEasternUrbanCohortHospital-basedProspectiveAdult patients (>18 years) admitted for heart failureNo43.546.4>18463Framingham's criteria
Sani, 2017 [33]The THESUS-HF registrySSACohortHospital-basedProspectivePatients presenting with acute heart failureNo49.252.3>12954European Society of Cardiology guidelines on HF
Ogah, 2014 [34]NigeriaWesternUrbanCohortHospital-basedProspectivePatients followed up for heart failureNo53.158.0NR239NR
Carlson, 2017 [35]Kenya; UgandaEasternNRCross sectionalHospital-basedProspectiveHealth facilities with available diagnostic technologies for HF diagnosisNoNANANA340 health facilities (197 in Uganda and 143 in Kenya)NA

HF=Heart failure; THESUS-HF=sub-Saharan Africa Survey for Heart Failure; INTER-CHF=INTERnational Congestive Heart Failure; NR=Not reported; NA=Not applicable; SSA=Sub-Saharan Africa.

Table 4

Summary tables for studies reporting on the prevalence of heart failure sub-Saharan Africa.

First name of author, publication yearCountryRegionAreaStudy designStudy settingData collectionRandom samplingPopulationMale (%)Mean ageAge range (in years)Sample sizeHF diagnostic toolPrevalence of HF (%)Study quality
Osuji, 2014 [20]NigeriaWesternNRCross-sectionalHospital-basedRetrospectiveNoPatients admitted to the medical ward50.560.718–110537NR30.9Moderate
Kingue, 2005 [3]CameroonCentralUrbanChart reviewHospital-basedRetrospectiveNoPatient >16 years admitted for cardiac pathologies59.357.3NR144Echocardiography30Moderate
Ansa, 2016 [24]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveNoAll cases of medical admissions38.95547–65339NR42.5Low
Pio, 2014 [18]TogoWesternUrbanCross-sectionalHospital-basedRetrospectiveNoPatients admitted to the cardiology unitNR52.218–106297Echocardiagraphy25.6High
Pio, 2014 [19]TogoWesternUrbanCross-sectionalHospital-basedRetrospectiveNoPatients admitted to the cardiology unitNR36.518–45376Echocardiagraphy28.6Low
Ogah, 2014 [17]NigeriaWesternUrbanCohortHospital-basedProspectiveNoAll medical admission54.956.4NR452Echocardiagraphy9.4High
Adeoti, 2015 [23]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveNoAll medical admissions55.050.916–1023750NR11.0Moderate

NR=Not reported.

Table 5

Aetiologies of heart failure across sub-Saharan Africa (1996–2017).

First name of author, publication yearCountryRegionAreaStudy designStudy settingData collectionStudy populationRandom samplingMale (%)Mean age (in years)Age range (in years)Sample sizeCriteria for diagnosis of HFAetiology of heart failureDiagnostic criteria of IHDStudy quality
Oyoo, 1999 [1]KenyaEasternUrbanCross-sectionalHospital-basedProspectivePatients ≥13 years admitted for congestive heart failureNo48.4NR≥1391NRRheumatic heart disease (32%); Cardiomyopathy (25.2%); Hypertensive heart disease (17.6%), pericardial disease (13.2%); Cor pulmonale (7.7%); Ischaemic heart disease (2.2%); Congenital heart disease (2.2%).ECG and 2D Doppler EchocardiographyModerate
Thiam, 2003 [2]SenegalWesternUrbanCross-sectionalHospital- basedProspectivePatients suffering from heart failureNoNR50.012–91170NRHypertension heart disease (34%); Valvular heart diseases (45%); Chronic renal failure (14.5%); Ischaemic heart disease (18.9%); Pulmonary embolism with Right heart failure (3.5%) and aetiology unspecified (6%)Clinical presentation ECG and EchocardiographyHigh
Kingue, 2005 [3]CameroonCentralUrbanCross-sectionalHospital-basedRetrospective and prospectivePatients presenting with clinical and echocardiographic signs of heart failureNo59.357.3≥16167NRHypertensive heart disease (54.5%); Cardiomyopathies (26.3%); Rheumatic heart disease (24.6%), Valvular heart diseases (24.6%), Ischaemic heart disease (2.4%).12-lead ECG and EchocardiographyModerate
Familoni, 2007 [4]NigeriaWesternSemi-urbanCross-sectionalHospital-basedProspectivePatients presenting with acute heart failureNo61.757.6NR82NRHypertensive heart disease (43.4%); Dilated cardiomyopathy (28%); Rheumatic heart disease (9.8%), Endomyocardial fibrosis (2.2%); Cor pulmonale (3.7%); Ischaemic heart disease (8.5%); others (3.5%)NRModerate
Owusu, 2007 [5]GhanaWesternUrbanCross-sectionalHospital-basedProspectivePatients above 12 years admitted with diagnosis of heart failureNo51.551.113–90167Framingham criteriaHypertensive heart disease (42.5%); Rheumatic heart disease (21.6%); Dilated cardiomyopathy (17.4%); pericardial disease (4.2%); Ischaemic heart disease (3.6%); Cor pulmonale (2.4%) and Congenital heart disease (2.4%)12-lead ECG and EchocardiographyHigh
Stewart, 2008 [6]South AfricaSouthernUrbanCross-sectionalHospital-basedProspectiveNovo presentations in patients with heart failure and related cardiomyopathiesNo4355.0NR884ESCDilated cardiomyopathy (35%); Hypertensive heart disease (33%); Right heart failure (27%); Ischaemic heart disease (9%) and Valvular heart disease (8%)12-lead ECG; echocardiography; stress test; cardiac nuclear imaging and cardiac catheterizationHigh
Ogah, 2008 [7]NigeriaWesternUrbanCross-sectionalHospital-basedRetrospectiveAll cases of echocardiography done in the department of medicine between September 2005 and February 2007No51.654.015–901441NRHypertensive heart disease (56.7%); Rheumatic heart disease (3.7%); Dilated cardiomyopathy (3.0%); Pericardial disease (1.8%); cor pulmonale (1.6%); Ischaemic heart disease (0.6%); Congenital heart disease (0.4%); diabetic heart disease (0.4%); thyroid heart disease (0.1%); Sickle cell cardiopathy (0.1%).NRHigh
Onwuchekwa, 2009 [8]NigeriaWesternNRCross-sectionalHospital-basedRetrospectiveCongestive cardiac failure cases admitted and/or discharged from the medical wardsNo57.254.418–100423Framingham criteriaHypertensive heart disease (56.3%); Cardiomyopathies (12.2%); Chronic renal failure (7.80%); Severe anemia (4.72%); Rheumatic heart diseases (4.26%). Cor pulmonale (2.13%); Congenital valvular heart disease (0.24%); Ischemic heart disease (0.24%); Missing (11.11%)12-lead ECG; echocardiographyModerate
Damasceno, 2012 [10]The THESUS-HF registrySSACohortHospital-basedProspectivePatients admitted with acute heart failureNo49.252.3˃121006European Society of Cardiology (ESC) guidelines on HFHypertensive heart disease (45.4); Idiopathic dilated cardiomyopathy (18.8%); Rheumatic heart disease (14.3%); Ischaemic heart disease (7.7%); Peripartum cardiomyopathy (7.7%); Pericardial tamponade (6.8%); HIV cardiomyopathy (2.6%); Endomyocardial fibrosis (1.3%).12-lead ECG; echocardiography; stress testModerate
Kwan, 2013 [12]RwandaEasternRuralCross-sectionalHospital-basedRetrospectiveHeart failure patients treated between November 2006 and march 2011No30.0NRNR138NRDilated cardiomyopathy (54%), Rheumatic heart disease (25%), hypertensive heart disease (8%) and ischaemic heart disease (0%)NRModerate
Massouré, 2013 [13]DjiboutiEasternNRCohortHospital-basedProspectiveAdults hospitalized for heart failureNo84.055.827–7545Framingham criteriaCoronary artery disease (62%); hypertensive heart disease (18%); rheumatic valvular disease (13%) and primary dilated cardiomyopathy (7%)12-lead ECG; echocardiography; stress testModerate
Ojji, 2013 [14]NigeriaWesternUrbanCross-sectionalHospital-basedProspectivePatients with novo presentations of heart diseaseNo49.349.0NR1515European Society of Cardiology (ESC) guidelines on HFHypertensive heart disease (60.6%); Idiopathic dilated cardiomyopathy (12.0%); Valvular rheumatic heart disease (8.6%); peripartum cardiomyopathy (5.3%); Alcoholic cardiomyopathy (4.2%); Thyrotoxic heart disease (2.9%); right heart failure (2.5%); Ischaemic heart disease (0.4%)ECG; Cardiac enzymes; EchocardiographyHigh
Makubi, 2014 [16]TanzaniaEasternUrbanCohortHospital-basedProspectivePatients ≥18 years of age with heart failure defined by the Framingham criteriaNo49.055.0≥18427Framingham criteriaHypertensive heart disease (45%); Cardiomyopathy (28%); Rheumatic heart disease (12%); Ischaemic heart disease (9%); Othersa (6%)12-lead ECG; echocardiography; angiographyHigh
Ogah, 2014 [17]NigeriaWesternUrbanCross-sectionalHospital-basedProspectivePatients presenting with acute heart failureNo54.956.4NR452Framingham criteria and ESCHypertensive heart disease (78.5%); Dilated cardiomyopathy (7.5%); Cor pulmonale (4.4%); Pericardial disease (3.3%); Rheumatic heart disease (2.4%); Ischaemic heart disease (0.4%)12-lead ECG and EchocardiographyHigh
Pio, 2014 [18]TogoWesternUrbanCross-sectionalHospital-basedProspectiveHospitalized patients with heart failureNo48.252.218–106297European Society of Cardiology (ESC) guidelines on HFHypertensive heart disease (43.1%); Ischaemic heart disease (19.2%); Peripartum cardiomyopathy (11.8%); valvulopathies (11.8%); HIV-related cardiopathy (3.4%); Thyrotoxic heart disease (3%); Cor pulmonale (2.7%); congenital cardiopathies (2.7%); Chronic alcoholism (2%) and idiopathic (5.9%).ECG; Cardiac enzymes; EchocardiographyHigh
Pio, 2014 [19]TogoWesternUrbanCross-sectionalHospital-basedRetrospectiveFiles of patients hospitalized with heart failureNoNR36.518–45376NRHypertensive heart disease (42.8%); Valvulopathies (18.1%); Peripartum cardiomyopathy (15.4%); Idiopathic dilated cardiomyopathy (5.8%); Alcoholic cardiomyopathy (3.2%); IHD (2.7%); Congenital cardiopathy (2.7%); Cor pulmonale (2.1%); thyrotoxic heart failure (1.8%); Pericardial tamponade (1.1%) and HIV-associated myocarditis (1.1%)ECG; Cardiac enzymes; EchocardiographyLow
Dokainish, 2015 [22]The INTER-CHF registrySSACohortHospital-basedProspective, international, multicenterAmbulatory and hospitalized adult patients with heart failureYes51.853.4≥181294Boston criteria of HFHypertensive heart disease (35%); Ischaemic cardiomyopathy (20%); Idiopathic dilated cardiomyopathy (14.5%); Valvular rheumatic heart disease (7.2%); Endocrine/metabolic heart disease (5.3%); Vavlular non-rheumatic heart disease (2.3%); Alcohol/drug induced cardiopathy (0.7%); HIV cardiomyopathy (0.7%).12-lead ECG; echocardiographyModerate
Ansa, 2016 [24]NigeriaWesternNRCross-sectionalHospital-basedRetrospective medical record reviewAll cardiovascular admissions to the medical wardsNoNRNR≥18144NRHypertensive heart disease (48.6%); dilated cardiomyopathy (35.4%); Anaemia (14.6%) and Rheumatic heart disease (1.4%)NRLow
Abebe 2016 [25]EthiopiaEasternUrbanChart reviewHospital-basedRetrospectiveMedical records of patients admitted for heart failureNR30.253.6NR311NRValvular heart disease (40.8%); Hypertensive heart disease (16.1%); Ischaemic heart disease (15.8%); Dilated cardiomyopathy (12.5%), Cor pulmonale (4.5%); Others (10.3%)NRModerate
Kingery, 2017 [27]TanzaniaEasternUrbanCohortHospital-basedProspectiveMedical inpatients admitted for heart failureNo44.152.0≥18145Framingham criteria of HFHypertensive heart disease (42.8%); dilated cardiomyopathy (19.3%); Valvular heart disease (16.6%); cor pulmonale (7.6%); ischaemic heart disease (6.2%); Other causes (7.6%)12-lead ECG; echocardiographyHigh
Boombhi, 2017 [28]CameroonCentralUrbanCross-sectionalHospital-basedRetrospectivePatients hospitalized for acute heart failure, diagnosed on clinical and/or ultrasound evidenceNo42.761,516–95148NRHypertensive heart disease (30.16%); Dilated cardiomyopathy (28.57%); Valvular heart disease (11.90%); Chronic cor pulmonale (8.73%); Ischemic heart disease (6.35%); Pericardial diseases (3.96%); Peripartum cardiomyopathy (3.18%)12-lead ECG; echocardiographyLow
Traore, 2017 [29]Ivory CoastWesternUrbanCross-sectionalHospital-basedRetrospectivePatients hospitalized for heart failureNo51.0NRNR257NRHypertensive heart disease (22.9%); Dilated cardiomyopathy (55.57%); Valvular heart disease (6.76%); Ischemic heart disease (11.23%); Other (9.9%)Echocardiography ± coronarographyLow

Othersa=Tuberculosis; HIV-related cardiomyopathy; endomyocardial fibrosis; obstructive pulmonary disease; IHD=Ischaemic heart disease; ECG=Electrocardiography; HF=Heart failure; THESUS-HF=sub-Saharan Africa Survey for Heart Failure; INTER-CHF=INTERnational Congestive Heart Failure; ESC=European Society of Cardiology; NR=not reported.

Table 6

Summary of studies reporting on pharmacologic treatment of heart failure in sub-Saharan Africa.

First name of author, publication yearCountryRegionAreaStudy designStudy settingData collectionRandom samplingMale (%)Mean age (in years)Age range (in years)Sample sizeCriteria for diagnosis of HFTreatment of heart failureStudy quality
Kingue, 2005 [10]CameroonCentralUrbanCross-sectionalHospital-basedRetrospective and prospectiveNo59.357.3≥16167NRLoop diuretics (90%); angiotensin-converting enzyme inhibitor (ACEI) (64.7%); beta-blockers (19.8%); digoxin (30.5%); aldosterone antagonists (25.5%)Moderate
Stewart, 2008 [7]South AfricaSouthernUrbanCross-sectionalHospital-basedProspectiveNo43.055.0NR844ESCLoop or thiazide diuretic (68%); ACEI (57.7%); beta-blocker (45.6%); digoxin (19%); aldosterone antagonist (42%); calcium channel blocker (18%)High
Ogah, 2014 [26]NigeriaWesternUrbanCohortHospital-basedProspectiveNo54.956.4NR452Framingham criteria and ESCLoop diuretic (88.1%); ACEI (99.1%); beta-blockers (9.1%) digoxin (72.3%); long-acting calcium-channel blockers (26.8%); combined hydralazine and isosorbide dinitrate (14.4%)High
Damasceno, 2012 [17]THESUS-HF RegistrySSANRCohortHospital-basedProspectiveNo49.252.3˃121006ESCLoop diuretic (79%); ACEI/angiotensin receptor blocker (ARB) (82%); beta-blockers (30%); Digoxin (60%); Aldosterone antagonist (75%);Moderate
Makubi, 2014 [18]TanzaniaEasternUrbanCohortHospital-basedProspectiveNo49.055.0≥18427Framingham criteriaLoop diuretics (88%); ACEI/ARB (92%); β-Blockers (42%); Digoxin (39%); Aldosterone antagonist (72%); Calcium channel blockers (19%); Nitrates (64%); Hydralazine (4%)High
Dokainish, 2016 [19]INTER-CHF registrySSABothCohortHospital-basedProspective, international, multicenterNo51.853.4≥181294Boston criteria of HFDiuretic (93.7%); ACEI/ARB (77.1%); β-Blockers (48.3%); Digoxin (31.9%); Aldosterone Inhibitors (59.4%);Moderate
Boombhi, 2017 [29]CameroonCentralUrbanCross-sectionalHospital-basedRetrospectiveNo42.761.516–96148NRDiuretics (93.2%); ACEI/ARB (50%); Beta-blockers (20.6%)Low
Bonsu, 2017 [30]GhanaWesternUrbanCohortHospital-basedRetrospectiveNo45.660.3≥181488Framingham criteria of HFDiuretics (68.4%); ACEI/ARB (62%); β-Blockers (32.5%); Digoxin (16.3%); Aldosterone antagonist (28%); Calcium channel blockers (44.9%); Nitrates (2.1%)Low
Mwita, 2017 [31]BotswanaSouthernUrbanCohortHospital-basedProspectiveNo53.954.220–89193NRACEI/ARB (67.4%); β-Blockers (72.1%); Loop diuretics (86%); Digoxin (22.1%); Aldosterone antagonist (59.9%)Moderate
Table 7

Summary of studies reporting on the mortality rate and/or predictors of mortality among heart failure patients in sub-Saharan Africa.

First name of author, publication yearCountryRegionAreaStudy settingData collectionRandom samplingStudy PopulationMale (%)Mean age (in years)Age range (in years)Sample sizeDuration of follow-upMortality ratePredictor(s) of mortality (HR* or OR**)Study quality
Familoni, 2007 [4]NigeriaWesternSemi-UrbanHospital-basedProspectiveNoAdult patients (>18 years) admitted for acute heart failure67.157.6NR823 years3-year mortality rate=67.1%Age (HR=0.997); Systolic blood pressure (HR=1.002); Congestion score (HR=1.007)Moderate
Maro, 2009 [9]TanzaniaEasternUrbanHospital-basedProspectiveNoPatients admitted for congestive heart failure55.0NRNR36012 months360-day mortality rate=21.9%NRModerate

































Chansa, 2012 [11]ZambiaSouthernUrbanHospital-basedProspectiveNoAdult patients (>18 years) admitted for acute heart failure4150NR39030 daysIn-hospital mortality rate=24.1%Left ventricular ejection fraction <40% (HR=1.93); NYHA class IV (HR=1.92); Serum urea nitrogen >15 mmol/L (HR=2.10); Haemoglobin levels <12 g/dL (HR=1.34); Systolic blood pressure <115 mmHg (HR=1.92)Moderate
30-day mortality rate=35%

































Sliwa, 2013 [15]The THESUS-HF registrySSAHospital-basedProspectiveNoPatients presenting with acute heart failure49.152.3NR1006Six months60-day mortality rate=9.5%Malignancy (HR=5.04); History of cor pulmonale (HR=2.50); Serum urea nitrogen (HR=1.39); Systolic blood pressure (HR=0.91); Rales (HR=2.18); West region (HR=1.83)High
180-day mortality rate=15.0%
Massouré, 2013 [13]DjiboutiEasternUrbanHospital-basedProspectiveNoAdult patients (> 18 years) admitted for heart failure8455.827–754514.4 monthsMortality rate=18.0%NRModerate
Okello, 2014 [21]UgandaEasternNRHospital-basedRetrospectiveNoPatients admitted for acute heart failure30.352NR27413 monthsIn-hospital mortality rate=18.3%Hypotension on admission (adjusted OR=4.6); Reduced left ventricular ejection fraction (adjusted OR=7.6)Low
Makubi, 2014 [16]TanzaniaEasternUrbanHospital-basedProspectiveNoAdult patients (>18 years) with heart failure49.055>184277 months22.4 per 100 person-yearsCreatinine clearance (HR=0.98); Pulmonary hypertension (HR=2.11); Anaemia (HR=2.27); No formal education (HR=2.34); Inpatient (HR=3.23); Atrial fibrillation (HR=3.37).High
Ali, 2016 [26]EthiopiaEasternUrbanHospital-basedProspectiveNoAdult patients (> 18 years) admitted for heart failure50.750.9>181529 monthsIn-hospital mortality rate=3.9%NRLow
Abebe, 2016 [25]EthiopiaEasternUrbanHospital-basedRetrospectiveNRAdult patients admitted for HF30.253.8>1831125 monthsMortality rate=14.1%Advanced age (HR=1.05), Hyponatremia (HR=0.91), elevated creatinine levels (HR=1.97), and absence of medication (spironolactone [HR=0.34], ACEI [HR=0.26] and statin [HR=0.19])Moderate

































Kingery, 2017 [27]TanzaniaEasternUrbanHospital-basedProspectiveNoAdult patients (>18 years) admitted for heart failure38.350.8>1814512 monthsIn-hospital mortality rate=25.2%Low eGFR (HR=2.94); Proteinuria (HR=2.03).High
360-day mortality rate=57.9%
Bonsu, 2017 [30]GhanaWesternUrbanHospital-basedRetrospectiveNoAdult patients (> 18 years) admitted for heart failure45.660.3>1814885 years5-year mortality rate=31.7%Age (HR=1.01); NYHA IV (HR=1.96); Ejection fraction (HR=0.99); LDLC-C (HR=1.1); Chronic kidney disease (HR=1.74); Atrial fibrillation (HR=1.26); Anaemia (HR=1.40); Diabetes mellitus (HR=1.50); Statin (HR=0.70); Aldosterone antagonists (HR=0.81)High

































Mwita, 2017 [31]BotswanaSouthernUrbanHospital-basedProspectiveNoAdult patients (>18 years) admitted for acute heart failure53.954.220–891931 yearIn-hospital mortality rate=10.9%Advanced age; Lower haemoglobin level; Lower eGFR; Lower serioum sodium levels; Higher length of hospital stay; Higher serum creatinine levels; Higher serum urea levels; Higher serum NT-proBNP levelsModerate
30-day mortality rate=14.7%
180-day mortality rate=30.8%
Pallangyo 2017 [32]TanzaniaEasternUrbanHospital-basedProspectiveNoAdult patients (>18 years) admitted for heart failure43.546.4>18463180 days180-day mortality rate=57.8%Renal dysfunction (HR=1.9); Severe anaemia (HR=1.8); Hyponatraemia (HR=2.2); Rehospitalisation (HR=4.3); Cardiorenal anaemia syndrome (HR=2.1)High

































Sani, 2017 [33]The THESUS-HF registrySSAHospital-basedProspectiveNoPatients presenting with acute heart failure49.252.3>12954180 daysNRPredictors of mortality within 60 days: Heart rate (HR=1.07); left atrial size (HR=1.00)Low
Predictors of mortality within 180 days: Heart rate >80bpm (HR=1.25); left ventricular posterior wall thickness in diastole >9 mm (HR=1.32); Presence of aortic stenosis (HR=3.60)

HR*=Hazard ratio; OR**=Odd's ratio; NYHA=New York Heart Association; bpm=Beats per minute; NR=Not reported; eGFR=Estimated glomerular filtration rate.

Summary table of included studies reporting on heart failure in sub-Saharan Africa (1996–2017). HF=Heart failure; THESUS-HF=sub-Saharan Africa Survey for Heart Failure; INTER-CHF=INTERnational Congestive Heart Failure; NR=Not reported; NA=Not applicable; SSA=Sub-Saharan Africa. Summary tables for studies reporting on the prevalence of heart failure sub-Saharan Africa. NR=Not reported. Aetiologies of heart failure across sub-Saharan Africa (1996–2017). Othersa=Tuberculosis; HIV-related cardiomyopathy; endomyocardial fibrosis; obstructive pulmonary disease; IHD=Ischaemic heart disease; ECG=Electrocardiography; HF=Heart failure; THESUS-HF=sub-Saharan Africa Survey for Heart Failure; INTER-CHF=INTERnational Congestive Heart Failure; ESC=European Society of Cardiology; NR=not reported. Summary of studies reporting on pharmacologic treatment of heart failure in sub-Saharan Africa. Summary of studies reporting on the mortality rate and/or predictors of mortality among heart failure patients in sub-Saharan Africa. HR*=Hazard ratio; OR**=Odd's ratio; NYHA=New York Heart Association; bpm=Beats per minute; NR=Not reported; eGFR=Estimated glomerular filtration rate. Data were analyzed using the ‘meta’ package of R software. A random-effects meta-analysis model was used to pool prevalence estimates after stabilization of the variance of the study-specific prevalence using the Freeman-Tukey single arc-sine transformation [37]. The Egger's test was used to assess publication bias which was considered significant if the p-value <0.1. Summary statistics from meta-analyses of prevalence studies on the medications used to treat heart failure in sub-Saharan Africa are presented in Table 8.
Table 8

Summary statistics from meta-analyses of prevalence studies on the medications used to treat heart failure in sub-Saharan Africa.

TreatmentN studiesN participants% (95% confidence interval)I² (95% confidence interval)H (95% confidence interval)P heterogeneityP Egger test
ACEI/ARB9569275.5 (64.4–85.1)98.8 (98.4–99.0)8.9 (7.8–10.2)<0.00010.879
Aldosterone antagonists6492551.5 (32.4–70.3)99.4 (99.3–99.6)13.4 (11.8–15.2)<0.00010.807
Digoxin7502731.5 (19.4–45.0)98.9 (98.6–99.2)9.6 (8.3–11.2)<0.00010.924
Loop diuretics9569281.6 (72.7–89.1)98.4 (97.8–98.8)7.8 (6.7–9.0)<0.00010.806
β-Blockers9569231.4 (22.6–41.0)98.1 (97.4–98.6)7.3 (6.3–8.5)<0.00010.549

ACEI=Angiotensin II enzyme inhibitor; ARB=Angiotensin receptor blocker; N=frequency; CI=confidence interval.

Summary statistics from meta-analyses of prevalence studies on the medications used to treat heart failure in sub-Saharan Africa. ACEI=Angiotensin II enzyme inhibitor; ARB=Angiotensin receptor blocker; N=frequency; CI=confidence interval. These data are attached to a systematic review and meta-analysis published in the International Journal of Cardiology [38].
Subject areaMedicine
More specific subject areaCardiology
Type of dataData presented in tables and figures
How data was acquiredSystematic search of literature
Data formatRaw and analyzed data
Experimental factorsNot applicable
Experimental featuresNot applicable
Data source locationNot applicable
Data accessibilityAll data are included in this article
Related research articleHeart failure in sub-Saharan Africa: a contemporaneous systematic review and meta-analysis. International Journal of Cardiology; In Press
  31 in total

1.  Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement.

Authors:  Damian Hoy; Peter Brooks; Anthony Woolf; Fiona Blyth; Lyn March; Chris Bain; Peter Baker; Emma Smith; Rachelle Buchbinder
Journal:  J Clin Epidemiol       Date:  2012-06-27       Impact factor: 6.437

2.  Contemporary profile of acute heart failure in Southern Nigeria: data from the Abeokuta Heart Failure Clinical Registry.

Authors:  Okechukwu S Ogah; Simon Stewart; Ayodele O Falase; Joshua O Akinyemi; Gail D Adegbite; Albert A Alabi; Akinlolu A Ajani; Julius O Adesina; Amina Durodola; Karen Sliwa
Journal:  JACC Heart Fail       Date:  2014-04-30       Impact factor: 12.035

3.  [A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: experience of the medicine department at Yaounde General Hospital].

Authors:  S Kingue; A Dzudie; A Menanga; M Akono; M Ouankou; W Muna
Journal:  Ann Cardiol Angeiol (Paris)       Date:  2005-09

4.  Readmission and death after an acute heart failure event: predictors and outcomes in sub-Saharan Africa: results from the THESUS-HF registry.

Authors:  Karen Sliwa; Beth A Davison; Bongani M Mayosi; Albertino Damasceno; Mahmoud Sani; Okekuchwu S Ogah; Charles Mondo; Dike Ojji; Anastase Dzudie; Charles Kouam Kouam; Ahmed Suliman; Neshaad Schrueder; Gerald Yonga; Sergine Abdou Ba; Fikru Maru; Bekele Alemayehu; Christopher Edwards; Gad Cotter
Journal:  Eur Heart J       Date:  2013-09-18       Impact factor: 29.983

5.  Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study.

Authors:  Abel Makubi; Camilla Hage; Johnson Lwakatare; Peter Kisenge; Julie Makani; Lars Rydén; Lars H Lund
Journal:  Heart       Date:  2014-04-17       Impact factor: 5.994

6.  Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities.

Authors:  Simon Stewart; David Wilkinson; Craig Hansen; Vinesh Vaghela; Robert Mvungi; John McMurray; Karen Sliwa
Journal:  Circulation       Date:  2008-11-24       Impact factor: 29.690

7.  Pattern of cardiovascular admissions at Nnamdi Azikiwe University Teaching Hospital Nnewi, South East Nigeria.

Authors:  Charles Ukachukwu Osuji; Emmanuel Ikechukwu Onwubuya; Gladys Ifesinachi Ahaneku; Emeka Godwin Omejua
Journal:  Pan Afr Med J       Date:  2014-02-18

8.  Hyponatremia in patients hospitalized with heart failure: a condition often overlooked in low-income settings.

Authors:  Khalid Ali; Abdulhalik Workicho; Esayas Kebede Gudina
Journal:  Int J Gen Med       Date:  2016-08-01

9.  Pattern of heart failure in a Nigerian teaching hospital.

Authors:  Arthur C Onwuchekwa; Godspower E Asekomeh
Journal:  Vasc Health Risk Manag       Date:  2009-09-18

10.  A clinical study of pattern and factors affecting outcome in Nigerian patients with advanced heart failure.

Authors:  O B Familoni; T O Olunuga; B W Olufemi
Journal:  Cardiovasc J Afr       Date:  2007-10-22       Impact factor: 1.167

View more
  14 in total

Review 1.  An overview of heart failure in low- and middle-income countries.

Authors:  Valirie N Agbor; Ntobeko A B Ntusi; Jean Jacques Noubiap
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

2.  Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors among Heart Failure Patients in Southwest Ethiopia.

Authors:  Yirga Legesse Niriayo; Kabaye Kumela; Kidu Gidey; Mulugeta Tarekegn Angamo
Journal:  Biomed Res Int       Date:  2019-04-24       Impact factor: 3.411

3.  PASCAR and WHF Cardiovascular Diseases Scorecard project.

Authors:  Mpiko Ntsekhe; Jean M Fourie; Wihan Scholtz; Oana Scarlatescu; George Nel; Karen Sliwa
Journal:  Cardiovasc J Afr       Date:  2021 Jan-Feb       Impact factor: 1.167

4.  Healthcare-seeking behaviour, barriers to care and predictors of symptom improvement among patients with cardiovascular disease in northern Tanzania.

Authors:  Julian T Hertz; Francis M Sakita; Godfrey L Kweka; Zak Loring; Nathan M Thielman; Gloria Temu; John A Bartlett
Journal:  Int Health       Date:  2019-12-15       Impact factor: 3.131

5.  Prevalence, awareness, treatment, and control of hypertension in Cameroonians aged 50 years and older: A community-based study.

Authors:  Frank L Tianyi; Valirie N Agbor; Alfred K Njamnshi
Journal:  Health Sci Rep       Date:  2018-04-27

6.  Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies.

Authors:  Jean Jacques Noubiap; Valirie N Agbor; Jean Joel Bigna; Arnaud D Kaze; Ulrich Flore Nyaga; Bongani M Mayosi
Journal:  Sci Rep       Date:  2019-11-19       Impact factor: 4.379

7.  Tackling heart failure in sub-Saharan Africa: the imperious need for hypertension prevention and control.

Authors:  Jean Jacques Noubiap
Journal:  Pan Afr Med J       Date:  2020-08-31

8.  Adherence to antihypertensive drug treatment in Argentina: A multicenter study.

Authors:  Walter Espeche; Martin R Salazar; Rodrigo Sabio; Alejandro Diaz; Carlos Leiva Sisnieguez; Daniel Olano; Eduardo Balbin; Nicolas Renna; Pedro Grosse; Roberto A Flores; Ana C Lagos; Pablo Ferrer; Silvia Poppe; Facundo Risso Patron; Victor D Sotnieczuk Stasiuk; Elina Valentini; Jose R Cardozo; Jose R Romano; Roberto Parodi; Horacio Carbajal
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-17       Impact factor: 3.738

9.  Spectrum of heart failure in sub-Saharan Africa: data from a tertiary hospital-based registry in the eastern center of Burkina Faso.

Authors:  Dakaboué Germain Mandi; Joel Bamouni; Rélwendé Aristide Yaméogo; Dangwé Temoua Naïbé; Elisé Kaboré; Yibar Kambiré; Koudougou Jonas Kologo; Georges Rosario Christian Millogo; Patrice Zabsonré
Journal:  Pan Afr Med J       Date:  2020-05-21

10.  Non-adherence to antihypertensive pharmacotherapy in Buea, Cameroon: a cross-sectional community-based study.

Authors:  Nkengla Menka Adidja; Valirie Ndip Agbor; Jeannine A Aminde; Calypse A Ngwasiri; Kathleen Blackett Ngu; Leopold Ndemnge Aminde
Journal:  BMC Cardiovasc Disord       Date:  2018-07-24       Impact factor: 2.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.